Entrada Therapeutics Inc TRDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TRDA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $14.49
- Day Range
- $14.54–14.79
- 52-Week Range
- $10.62–18.44
- Bid/Ask
- $14.51 / $14.79
- Market Cap
- $494.57 Mil
- Volume/Avg
- 3,635 / 78,652
Key Statistics
- Price/Earnings (Normalized)
- 22.52
- Price/Sales
- 2.93
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 159
- Website
- https://www.entradatx.com
Comparables
Valuation
|
Metric
|
TRDA
|
PEPG
|
RNA
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.52 | — | — |
Price/Book Value | 1.77 | 3.04 | 3.40 |
Price/Sales | 2.93 | — | 209.60 |
Price/Cash Flow | 14.37 | — | — |
Price/Earnings
TRDA
PEPG
RNA
Financial Strength
|
Metric
|
TRDA
|
PEPG
|
RNA
|
|---|---|---|---|
Quick Ratio | 2.33 | 15.56 | 12.34 |
Current Ratio | 2.38 | 15.78 | 12.47 |
Interest Coverage | — | — | — |
Quick Ratio
TRDA
PEPG
RNA
Profitability
|
Metric
|
TRDA
|
PEPG
|
RNA
|
|---|---|---|---|
Return on Assets (Normalized) | 7.11% | −40.24% | −28.01% |
Return on Equity (Normalized) | 14.48% | −50.31% | −31.89% |
Return on Invested Capital (Normalized) | 7.18% | −46.81% | −35.83% |
Return on Assets
TRDA
PEPG
RNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vtphgbptx | Fgffb | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vcngpdk | Knqmct | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dvkbhzjyy | Rdxhxt | $107.8 Bil | |
MRNA
| Moderna Inc | Rrmnjssy | Pdt | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Gkwrtqxq | Hrfrt | $22.2 Bil | |
ARGX
| argenx SE ADR | Frdvnllg | Xwtlj | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vmzvspsg | Sntplt | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ppmvlpqnm | Bhyfyl | $15.1 Bil | |
INCY
| Incyte Corp | Prtlqchgf | Nsgccr | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dfxjvprjjl | Qttxky | $12.7 Bil |